| Entry |
|
|---|
| Name |
Pegapamodutide (USAN/INN) |
|---|
| Structure |
 |
|---|
| Class |
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01493 GLP-1 receptor agonist
Unclassified
DG03355 Oxyntomodulin analog
|
|---|
| Efficacy |
Antidiabetic, Glucagon-like peptide 1 (GLP-1) receptor agonist |
|---|
| Type |
Modified peptide |
|---|
| Comment |
Oxyntomodulin analog [CPD: C18197] [HSA: 2641] [KO: K05259]
Treatment of diabetes and obesity
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01493 GLP-1 receptor agonist
D10970 Pegapamodutide
Unclassified
DG03355 Oxyntomodulin analog
D10970 Pegapamodutide
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Secretin receptor family
Glucagon
GLP1R
D10970 Pegapamodutide (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
